20 (AIDX) Return on Sales (2025 - 2026)
20 (AIDX) reported Return on Sales of 0.05% for Q1 2026, down 3.0% on a YoY basis from 0.05% in Q1 2025, and down 249.28% quarter-over-quarter from 0.01% in Q1 2025.
20 (AIDX) Return on Sales (2025 - 2026) Analysis & Trends
20 has reported Return on Sales for 2 years, with the latest figure at 0.05% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 0.00% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 0.00% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 0.00% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 0.00% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 0.00% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.00% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 0.00% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 0.00% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | 20 | - | - | 62,884.00 | -0.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.05% |
| Mar 31, 2025 | -0.01% |